Methods of treating antibody-mediated rejection in organ transplant patients with c1-esterase inhibitor

A method for treating or preventing antibody- mediated rejection (AMR) of a transplanted organ comprising administration of a C1 esterase inhibitor (C1-INH) is provided. In particular, the treatment comprises administration according to a dosage regimen consisting of intravenous administration of th...

Full description

Saved in:
Bibliographic Details
Main Authors Broom, Colin, Uknis, Marc
Format Patent
LanguageEnglish
Published 26.08.2022
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:A method for treating or preventing antibody- mediated rejection (AMR) of a transplanted organ comprising administration of a C1 esterase inhibitor (C1-INH) is provided. In particular, the treatment comprises administration according to a dosage regimen consisting of intravenous administration of the C1-INH at an initial dose of about 5,000 units and six subsequent doses of 2,500 units given every other day for a total of 13 days of administration, wherein the administration occurs or is initiated in less than 5 to 10 days of organ transplantation, treatment with plasmapheresis and/or treatment with intravenous immunoglobulin (IVIg), and/or diagnosis of AMR of the patient.
Bibliography:Application Number: NZ20140759187